Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 9Dermatologic 4Thoracic 3Gynecologic 3Gastrointestinal 3Breast 2Sarcoma 1NET 1Lymphoid 1Genitourinary 1Endocrine 1

Conditions

Ovarian Neoplasms 16Uterine Cervical Neoplasms 8Melanoma 7Colorectal Neoplasms 7Fallopian Tube Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Neoplasm Metastasis 5Breast Neoplasms 5Recurrence 4Triple Negative Breast Neoplasms 3Pancreatic Neoplasms 3Head and Neck Neoplasms 3Carcinoma, Ovarian Epithelial 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Prostatic Neoplasms 2Neoplasms 2Lymphoma 2Endometrial Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Carcinoma, Merkel Cell 2Carcinoma, Hepatocellular 2Anus Neoplasms 2Vulvar Neoplasms 1Vulvar Diseases 1Vaginal Neoplasms 1Uterine Cervical Dysplasia 1Turcot syndrome 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

pembrolizumab 18Cyclophosphamide 9fludarabine 8Nivolumab 8cemiplimab 5Carboplatin 5atezolizumab 4Gemcitabine 4Filgrastim 4Drug Therapy 4Docetaxel 4Cisplatin 4palbociclib 3durvalumab 3Paclitaxel 3Interleukin-2 3Bortezomib 3fludarabine phosphate 2epacadostat 2belinostat 2avelumab 2amminedichloro(2-methylpyridine)platinum(II) 2aldesleukin 2Tobacco Use Cessation Devices 2Temozolomide 2SS1(dsFv)PE38 2Riluzole 2Peripheral Blood Stem Cell Transplantation 2Oncolytic Virotherapy 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × Interleukin-2 × Gynecologic × Clear all
NCT05395052 2023-09-21

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Fate Therapeutics

Phase 1 Terminated
5 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT05122221 2022-06-28

CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers

Corregene Biotechnology Co., Ltd

Phase 1 Unknown
12 enrolled
GastrointestinalGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡